GlassScriptPhysician profile
Joyce Tito
NPI 1972917649
$10,131.38
in general payments reported to CMS, 2019-2025
63 companies · $3,377 in 2025
The $3,377 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $1,027 · 2023: $1,888 · 2024: $3,730 · 2025: $3,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,097 · Long Term Medical Supply Or Device Loan: $881 · Education: $17.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,097.14 |
| Long Term Medical Supply Or Device Loan | $880.93 |
| Education | $17.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,087.18 | 2022-2025 | |
| Pfizer INC. | $686.25 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $553.02 | 2021-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $513.64 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Gilead Sciences, INC. | $455.59 | 2022-2025 | Trodelvy |
| Janssen Biotech, INC. | $422.94 | 2021-2025 | Rybrevant, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $382.78 | 2021-2025 | Enhertu, Imfinzi, Calquence |
| Incyte Corporation | $373.04 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Daiichi Sankyo INC. | $313.17 | 2022-2025 | Enhertu, Datroway |
| Celgene Corporation | $288.80 | 2022-2025 | Reblozyl, Breyanzi, Pomalyst |
| Eisai INC. | $268.86 | 2022-2025 | |
| Lilly USA, LLC | $258.38 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Tersera Therapeutics LLC | $254.28 | 2022-2025 | Zoladex |
| Abbvie INC. | $233.88 | 2022-2025 | |
| Genzyme Corporation | $180.23 | 2022-2024 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $179.09 | 2024-2025 | Alunbrig, Fruzaqla, Iclusig |
| Glaxosmithkline, LLC. | $144.23 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Astellas Pharma US INC | $139.28 | 2024-2025 | Xospata, Vyloy |
| Beigene USA, INC. | $124.34 | 2022-2025 | Brukinsa, Tevimbra |
| Puma Biotechnology, INC. | $112.61 | 2022-2025 | |
| Sobi, INC | $109.12 | 2023-2025 | |
| Amgen INC. | $106.84 | 2021-2023 | Kyprolis |
| Kite Pharma, INC. | $105.28 | 2023 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $103.54 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $95.98 | 2023-2025 | Myrisk |
| Seagen INC. | $92.24 | 2022-2023 | Adcetris, Tukysa, Tivdak |
| Geron Corporation | $81.38 | 2025 | Rytelo |
| Regeneron Healthcare Solutions, INC. | $80.63 | 2024-2025 | Libtayo, Lynozyfic |
| Kyowa Kirin, INC. | $72.72 | 2023-2025 | Poteligeo |
| Servier Pharmaceuticals LLC | $69.24 | 2023-2025 | |
| Mirati Therapeutics, INC. | $67.82 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $66.99 | 2023-2025 | Monoferric |
| Emd Serono, INC. | $64.68 | 2022-2024 | Bavencio |
| Legend Biotech USA INC. | $61.59 | 2024-2025 | Carvykti |
| Sumitomo Pharma America, INC. | $58.48 | 2023-2025 | Orgovyx |
| Syndax Pharmaceuticals, INC. | $56.26 | 2025 | |
| Immunocore Limited | $54.31 | 2025 | Kimmtrak |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.45 | 2024 | Gilotrif |
| Jazz Pharmaceuticals INC. | $52.20 | 2025 | |
| Genentech USA, INC. | $50.44 | 2024-2025 | Polivy, Alecensa, Tecentriq |
| Apellis Pharmaceuticals, INC. | $49.94 | 2023-2025 | Empaveli |
| Array Biopharma INC | $49.83 | 2023-2024 | Mektovi, Braftovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $49.46 | 2023 | Imbruvica |
| Blueprint Medicines Corporation | $39.96 | 2023-2024 | Ayvakit |
| Agios Pharmaceuticals, INC. | $38.37 | 2023-2025 | Pyrukynd |
| Karyopharm Therapeutics INC. | $36.89 | 2023-2024 | Xpovio |
| Aveo Pharmaceuticals, INC. | $36.48 | 2024-2025 | |
| Epizyme, INC. | $35.30 | 2022 | |
| Alexion Pharmaceuticals, INC. | $33.73 | 2024-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $27.72 | 2024 | Besremi |
| Stemline Therapeutics INC. | $26.41 | 2025 | Orserdu |
| Adc Therapeutics America, INC. | $24.72 | 2024 | |
| Telix Pharmaceuticals | $24.57 | 2023 | Illuccix |
| Adaptive Biotechnologies Corporation | $24.21 | 2023 | Clonoseq |
| Genmab U.S., INC. | $23.29 | 2024 | Epkinly |
| Tg Therapeutics, INC. | $23.06 | 2022 | |
| Boston Scientific Corporation | $22.19 | 2023 | Wavewriter Alpha Prime 16 |
| Ge Healthcare | $20.07 | 2022 | |
| Organon LLC | $19.28 | 2023 | Ontruzant |
| Ipsen Biopharmaceuticals, INC | $17.68 | 2024 | Somatuline Depot, Onivyde |
| Cti Biopharma Corp. | $14.52 | 2023 | Vonjo |
| Taiho Oncology, INC. | $14.50 | 2025 | |
| Rigel Pharmaceuticals, INC. | $5.42 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Tito listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.